{"filing":{"accession_number":"0001437749-26-023087","cik":"0001131343","ticker":"PRNAF","company_name":"ALTERITY THERAPEUTICS LTD","form":"6-K","filing_date":"2026-07-09","report_date":null,"primary_document":"athe20260709c_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131343/000143774926023087/athe20260709c_6k.htm"},"events":[{"id":16772,"run_id":15000,"accession_number":"0001437749-26-023087","anchor_item_number":"EX-99.1","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Alterity announced receipt of an A$3.98 million R\u0026D tax refund from the Australian Government for the 2025 financial year. This is a material cash inflow that affects the company's liquidity and funding position for its clinical programs, but does not fit neatly into standard event categories (not debt issuance, dividend, or capital raise). It is clearly a financial event—a government tax incentive payment—that would affect a reasonable investor's assessment of the company's cash position and runway.","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-07-09","form":"6-K","submitted_at":null,"items":[{"id":14969,"accession_number":"0001437749-26-023087","item_number":"EX-99.1","item_title":"ex_986208.htm","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Alterity announced receipt of an A$3.98 million R\u0026D tax refund from the Australian Government for the 2025 financial year. This is a material cash inflow that affects the company's liquidity and funding position for its clinical programs, but does not fit neatly into standard event categories (not debt issuance, dividend, or capital raise). It is clearly a financial event—a government tax incentive payment—that would affect a reasonable investor's assessment of the company's cash position and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:26:20.490494+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14969,"accession_number":"0001437749-26-023087","item_number":"EX-99.1","item_title":"ex_986208.htm","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Alterity announced receipt of an A$3.98 million R\u0026D tax refund from the Australian Government for the 2025 financial year. This is a material cash inflow that affects the company's liquidity and funding position for its clinical programs, but does not fit neatly into standard event categories (not debt issuance, dividend, or capital raise). It is clearly a financial event—a government tax incentive payment—that would affect a reasonable investor's assessment of the company's cash position and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:26:20.490494+00:00","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-07-09"}]}